Connection
Laura Ramsey to Cytochrome P-450 CYP2D6
This is a "connection" page, showing publications Laura Ramsey has written about Cytochrome P-450 CYP2D6.
|
|
Connection Strength |
|
 |
|
 |
|
3.696 |
|
|
|
-
Ramsey LB, Gaedigk A. CYP2D6*9 and *41: Does the Activity Value Assigned to these Alleles Need to be Reduced to more Accurately Predict Phenotype? Clin Pharmacol Ther. 2022 06; 111(6):1208-1211.
Score: 0.663
-
Rossow KM, Vaughn SE, Strawn JR, Van Driest SL, Ramsey LB. The need for a refined understanding of CYP2D6 in second-generation antipsychotic outcomes in children and adolescents. Pharmacogenomics. 2021 06; 22(8):447-450.
Score: 0.654
-
Jallaq SA, Verba M, Strawn JR, Martin LJ, DelBello MP, Ramsey LB. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. J Child Adolesc Psychopharmacol. 2021 02; 31(1):56-62.
Score: 0.621
-
Tang Girdwood S, Hall M, Antoon JW, Kyler KE, Williams DJ, Shah SS, Orth LE, Goldman J, Feinstein JA, Ramsey LB. Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid. JAMA Netw Open. 2024 02 05; 7(2):e2355707.
Score: 0.197
-
Kanu AA, Johnston MM, Poweleit EA, Vaughn SE, Strawn JR, Ramsey LB. Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents. J Child Adolesc Psychopharmacol. 2024 02; 34(1):34-41.
Score: 0.197
-
Men X, Taylor ZL, Marshe VS, Blumberger DM, Karp JF, Kennedy JL, Lenze EJ, Reynolds CF, Stefan C, Mulsant BH, Ramsey LB, M?ller DJ. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression. Clin Pharmacol Ther. 2024 May; 115(5):1065-1074.
Score: 0.197
-
Ramsey LB, Prows CA, Chidambaran V, Sadhasivam S, Quinn CT, Teusink-Cross A, Tang Girdwood S, Dawson DB, Vinks AA, Glauser TA. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center. Am J Health Syst Pharm. 2023 06 22; 80(13):852-859.
Score: 0.189
-
Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023 07; 114(1):69-76.
Score: 0.186
-
Edwards A, Teusink-Cross A, Martin LJ, Prows CA, Mehta PA, Ramsey LB. Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series. Clin Transl Sci. 2022 03; 15(3):610-618.
Score: 0.168
-
Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411.
Score: 0.158
-
Troy TF, Poweleit EA, Strawn JR, Martin LJ, Ramsey LB. The Influence of Pharmacodynamic Genes on Fluoxetine Response in Pediatric Anxiety and Depressive Disorders. J Child Adolesc Psychopharmacol. 2020 05; 30(4):276-277.
Score: 0.150
-
Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Obeng AO, Beitelshees AL, Bell GC, Blake K, Crona DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Johnson JA, Peterson JF, Empey PE, Skaar TC. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med. 2019 10; 21(10):2255-2263.
Score: 0.141
-
Honeycutt DC, Blom TJ, Ramsey LB, Strawn JR, Bruns KM, Welge JA, Patino LR, Singh MK, DelBello MP. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study. J Child Adolesc Psychopharmacol. 2024 02; 34(1):42-51.
Score: 0.049
-
Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Rua?o G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 07; 114(1):51-68.
Score: 0.047
-
Tuteja S, Salloum RG, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Bishop JR. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clin Transl Sci. 2022 02; 15(2):371-383.
Score: 0.042
-
Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A. A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clin Pharmacol Ther. 2020 01; 107(1):50-52.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|